Publication: JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment
JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment
Date
Date
Date
Citations
Zhang, Y., Liang, R., Chen, C.-W., Mallano, T., Dees, C., Distler, A., Reich, A., Bergmann, C., Ramming, A., Gelse, K., Mielenz, D., Distler, O., Schett, G., & Distler, J. H. W. (2017). JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Annals of the Rheumatic Diseases, 76(8), 1467–1475. https://doi.org/10.1136/annrheumdis-2016-210911
Abstract
Abstract
Abstract
OBJECTIVES: Janus kinase 2 (JAK2) has recently been described as a novel downstream mediator of the pro-fibrotic effects of transforming growth factor-β. Although JAK2 inhibitors are in clinical use for myelodysplastic syndromes, patients often rapidly develop resistance. Tumour cells can escape the therapeutic effects of selective JAK2 inhibitors by mutation-independent transactivation of JAK2 by JAK1. Here, we used selective JAK2 inhibition as a model to test the hypothesis that chronic treatment may provoke resistance by facilitati
Metrics
Views
Additional indexing
Creators (Authors)
Volume
Volume
Volume
Number
Number
Number
Page Range
Page Range
Page Range
Page end
Page end
Page end
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Views
Citations
Zhang, Y., Liang, R., Chen, C.-W., Mallano, T., Dees, C., Distler, A., Reich, A., Bergmann, C., Ramming, A., Gelse, K., Mielenz, D., Distler, O., Schett, G., & Distler, J. H. W. (2017). JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Annals of the Rheumatic Diseases, 76(8), 1467–1475. https://doi.org/10.1136/annrheumdis-2016-210911